Zim Laboratories Peer Comparison

NSE: ZIMLAB | BSE: 541400

₹135.00

₹1.20 (0.90%)

As on 23-Sep-2026 15:24IST

Market cap

₹710 Cr

Revenue (TTM)

₹397 Cr

P/E Ratio

192.1

P/B Ratio

2.4

Div. Yield

0 %

Edit

	Zim Laboratories	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Market cap (₹ Cr)	710	21,248	20,070	17,605	18,391
Revenue (₹ Cr)	397	2,287	1,682	3,230	2,570
Net Profit (₹ Cr)	3.70	678.07	273.51	666.92	735.15
Net Margin (%)	0.91	28.10	16.19	20.60	26.88
RoE (%)	1.35	19.73	11.15	18.75	19.16
Price to Earnings	192.07	31.94	67.50	27.34	25.02
Price-To-Book	2.44	5.79	7.47	4.37	4.17

Income Statement (₹ Cr)

	Zim Laboratories	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Operating Revenue	396.82	2,287.33	1,682.47	3,229.67	2,569.77
Total Income	407.72	2,413.29	1,689.83	3,237.12	2,735.39
Total Expenditure	368.62	1,490.75	1,203.91	2,090.06	1,628.14
EBITDA	28.20	796.58	478.55	1,139.61	941.63
Depreciation	20.49	78.10	126.01	281.06	57.58
EBIT	7.72	718.48	352.55	858.55	884.05
Interest	13.54	0.88	52.11	190.64	7.69
Other Income	10.90	125.96	7.37	7.45	165.62
Exceptional Items	0.00	0.00	12.16	-17.24	-49.16
Profit before Tax	5.07	843.56	319.96	658.12	992.82
Provision for Tax	1.38	165.49	46.45	-8.80	257.67
Profit after Tax	3.70	678.07	273.51	666.92	735.15

	Zim Laboratories	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Shareholder's Funds	296.15	3,586.42	2,591.20	3,902.67	4,202.90
Minority Interest	0.00	-12.71	0.00	-21.81	0.00
Non-Current Liabilities	52.84	28.74	266.35	1,392.75	91.50
Current Liabilities	190.39	385.94	848.06	2,077.10	627.48
Total Liabilities	539.75	4,037.51	3,705.61	7,246.72	4,921.88

	Zim Laboratories	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Non-Current Assets	257.82	1,291.22	2,525.44	5,617.77	770.28
Current Assets	275.81	2,585.66	1,109.77	1,539.85	3,803.22
Total Assets	539.75	4,037.51	3,705.61	7,246.72	4,921.88
Total Debt*	122.82	0.57	657.97	2,309.68	2.50
Net Current Assets	85.42	2,199.72	261.71	-537.25	3,175.74
Contingent Liabilities	10.10	17.53	160.01	51.57	370.49

	Zim Laboratories	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Cash From Operating Activities	49.53	523.24	342.18	537.99	967.57
Cash Flow from Investing Activities	-56.35	-582.30	-325.92	-369.46	-561.67
Cash from Financing Activities	28.19	-46.46	13.62	-313.53	-798.31
Net Cash Inflow / Outflow	21.37	-105.52	29.88	-145.00	-392.41

	Zim Laboratories	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
ROCE (%)	5.47	24.97	11.43	14.47	23.39
ROE (%)	1.35	19.73	11.15	18.75	19.16
ROA (%)	0.73	18.69	7.80	9.26	14.95
EBIT Margin (%)	1.94	31.41	20.95	26.58	34.40
Net Margin (%)	0.91	28.10	16.19	20.60	26.88
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Zim Laboratories	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Revenue Growth (%)	7.55	15.01	27.91	9.59	10.69
EBIT Growth (%)	-61.26	18.45	58.32	16.84	24.14
Net Profit Growth (%)	-60.63	19.61	149.56	62.68	-9.09
EPS Growth (%)	-60.34	17.73	-3.57	67.41	14.40
Book Value Growth (%)	17.07	26.75	9.67	36.71	-0.34

	Zim Laboratories	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Price / Earnings	174.93	31.75	72.10	26.76	23.69
Price / Book Value	2.47	5.75	7.52	4.38	4.15
Dividend Yield (%)	0.00	0.29	0.06	0.00	1.88
EV/EBITDA	28.26	25.26	43.51	17.46	16.11
Market Cap (₹ Cr)	320.30	11,439.22	6,819.66	17,980.08	21,592.90

	Zim Laboratories	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Debt to Equity	0.14	0.00	0.07	0.24	0.00
Short term debt to equity ratio	0.21	0.00	0.16	0.12	0.00
Current Ratio	1.45	6.70	1.31	0.74	6.06
Quick Ratio	0.96	5.59	0.88	0.53	5.31
Interest Coverage	1.37	959.59	7.14	4.45	130.11

	Zim Laboratories	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Debtors to sales (%)	27.48	36.10	30.84	21.07	7.07
Asset Turnover	0.78	0.63	0.48	0.45	0.52
Receivable days	105.27	121.68	113.81	63.88	26.06
Inventory Days	87.86	63.83	84.76	43.27	65.95
Payable days	157.18	108.28	101.94	151.85	81.01
Cash Conversion Cycle	35.94	77.23	96.62	-44.70	11.00

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.